Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: The Latin American Cohort

Urueta-Robledo, Juan; Ariza, Horacio; Jardim, José R.; Caballero, Andrés; García-Calderón, Andrés; Amábile-Cuevas, Carlos F.; Hernández-Oliva, Gerardo; Vivar-Orozco, Raul

doi:10.1016/j.rmed.2006.01.013

Cited by 22 publications

(17 citation statements)

References 12 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unless specified, most of the medications described in the following studies were administered orally. Table 1 presents comparative studies of short-course fluoroquinolone treatment and standard therapy (≥7 days) of anti micro bial agents on clinical and bacteriological outcomes in patients with AECB [7,[26][27][28][29][30][31][32][33][34][35][37][38][39][40][41][42][43][44].…”

Section: Search Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Short-course fluoroquinolones in acute exacerbations of chronic bronchitis

Gotfried¹,

Grossman

2010

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

It is estimated that 50-70% of acute exacerbations of chronic bronchitis (AECB) are caused by bacterial infections. Appropriate selection of antimicrobials may lead to better outcomes and reduced healthcare costs. Respiratory fluoroquinolones (moxifloxacin, levofloxacin and gemifloxacin) have a broad spectrum of activity against most AECB-causing pathogens and are used as first-line treatment in patients with comorbidity, severe airway obstruction or recurrent exacerbations. We review studies, identified through a MEDLINE search, that compared clinical efficacy and speed of recovery for short-course (≤ 5 days) fluoroquinolone therapy with commonly prescribed standard therapy (≥ 7 days). Among 177 studies reporting the use of fluoroquinolones for AECB treatment, 23 used a short-course regimen, shown to be at least as effective as standard therapy of 7 or more days duration. Furthermore, evidence suggests that short-course therapy offers faster resolution of symptoms, faster rate of recovery, fewer relapses, fewer and shorter hospitalizations, and longer time between recurrences.

show abstract

Section: Search Resultsmentioning

confidence: 99%

“…Bacteriological eradication rate was also similar in the two treatment groups: 92.8 and 93.8% in the moxifloxacin and levofloxacin groups, respectively. The authors suggested that short-course, once-daily moxifloxacin therapy has compliance advantages over other currently used therapies [40].…”

Section: Reviewmentioning

confidence: 99%

Short-course fluoroquinolones in acute exacerbations of chronic bronchitis

Gotfried¹,

Grossman

2010

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

show abstract

“…A study that compared moxifloxacin (400 mg/day for 5 days) to levofloxacin (500 mg/day for 7 days) in a cohort from Latin America with AECB reported equivalent efficacy for both therapies (clinical success 91 vs 94%, respectively) [49]. In this study, the average age was 59 ± 15 years for the moxifloxacin group and 61 ± 15 years for the levofloxacin group.…”

Section: Category Antibiotic Recommendationmentioning

confidence: 57%

Antibiotic therapy in elderly patients with acute exacerbation of chronic bronchitis

Albertson¹,

Chan²

2009

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

Chronic bronchitis (CB) is a critical component of chronic obstructive pulmonary disease (COPD). Emphysema, reversible airway disease and bronchiectasis also contribute to COPD. Elderly patients are at increased risk for COPD and its components - emphysema, CB and bronchiectasis. In addition, older patients are at increased risk for resistant organisms during episodes of acute exacerbation of CB (AECB). These organisms include the more common bacteria implicated in AECB, such as Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae, and less common nonenteric, Gram-negative organisms such as Pseudomonas aeruginosa. Risk-stratified antibiotic treatment guidelines for AECB appear to be useful, although they have not been prospectively validated for the general CB population, and especially not in the elderly CB population. Many of the AECB treatment guidelines that are stratified based on risk factors have recommended that the oral respiratory fluoroquinolone antibiotics (gemifloxacin, levofloxacin and moxifloxacin) play a second-line but pivotal role, particularly in patients who have failed initial antibiotic treatment for simple CB or as initial treatment for complicated CB.

show abstract

“…This result is compatible with that of a previous study comparing moxifloxacin with levofloxacin. 20 Our study has some limitations. As this was an investigator initiated academic project a double-blind study could not be conducted due to financial constraints and logistic problems.…”

Section: Discussionmentioning

confidence: 89%

Comparative study of efficacy and safety of garenoxacin and moxifloxacin in acute exacerbation of chronic bronchitis in COPD patients

Sinha

Srivastava

Punera

et al. 2018

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: Acute exacerbation of chronic bronchitis in COPD (AECB) is the major cause of morbidity, mortality and marked reduction in quality of life and imposes significant burden on both patients and healthcare systems. Bacterial infections causing AECB frequently require antibacterial treatment, so more evidences are needed to guide better antibiotic choice. Objective of the study was planned to compare efficacy and safety of Garenoxacin, a new fluoroquinolone versus moxifloxacin for treatment of Acute exacerbation of Chronic bronchitis in COPD patient.Methods: This was a prospective open label comparative study done in department of pharmacology and T.B & Chest of Government Medical College attached Dr Shusila Tiwari Hospital, Haldwani. 60 subjects with clinical symptoms suggestive of Anthonisen type II AECOPD (any two of following criteria: Increased dyspnea, cough, sputum purulence) were enrolled and randomized to receive either Moxifloxacin 400 mg once daily for 7 days or Garenoxacin 400mg once daily for 7 days. The primary outcome measure was clinical success rate at day 7 visit. Secondary outcome measures were changes in clinical global impression (CGI) scales and incidence of adverse events.Results: The mean age of patient was 60.98±9.9 years and 57.9±9.3 years in the Moxifloxacin and Garenoxacin groups. The clinical success rates were comparable with 86.2% in moxifloxacin group 84.6% and in garenoxacin group. Adverse effects were mild and self limiting. We observed two adverse effects in garenoxacin and three in moxifloxacin group.Conclusions: The result of study showed that garenoxacin is comparable to moxifloxacin in terms of efficacy and safety.

show abstract

Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: The Latin American Cohort

Cited by 22 publications

References 12 publications

Short-course fluoroquinolones in acute exacerbations of chronic bronchitis

Short-course fluoroquinolones in acute exacerbations of chronic bronchitis

Antibiotic therapy in elderly patients with acute exacerbation of chronic bronchitis

Comparative study of efficacy and safety of garenoxacin and moxifloxacin in acute exacerbation of chronic bronchitis in COPD patients

Contact Info

Product

Resources

About